Corporate Executive Team

Susanne Schaffert Susanne Schaffert was appointed Chairperson and President of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. Prior to this, Susanne was the Head of Region Europe at Novartis Oncology, where she was responsible for leading Novartis’ Oncology Business Unit in the European Region, marketing key products in lung, breast and renal cancer as well as hematology and coordinating the entire Oncology operations for EU countries. Susanne is a member of the Novartis Oncology Executive Committee and R&D Portfolio management board, as well as a member of the Board of Novartis AG Germany and the GSK JV OTC Board. From 2010 to 2012, Susanne served as the Head of Investor Relations for Novartis Group, reporting to the Chief Financial Officer. Before this, she served as Novartis Global Franchise Head for Immunology and Infectious Diseases. Susanne first joined Novartis Germany in 1995, as a sales representative, and she has held a series of positions in Sales & Marketing with increasing responsibilities in both National and Global functions. Her roles have included Global Brand Director, Basel; Head of Marketing Oncology, Germany; Business Unit Head Oncology, Germany and Head of Northern & Central Europe for Novartis Oncology, managing a $1 billion business with more than 500 associates. Susanne holds a Ph.D. with honors in Organic Chemistry from University of Erlangen (Germany).

Germo Gericke was appointed Head of Research and Development of Advanced Accelerator Applications (AAA), following the completion of a tender offer for the company by Novartis. Germo continues his role as a member of the Oncology Development Leadership Team at Novartis. Prior to joining AAA, Germo served as Franchise Global Program Head in the Oncology Global Development Unit of Novartis, where he leads cross-functional developent activities for compounds in full developent and life cycle management, including Sandostatin, Glivec, Afinitor, Exjade/Jadenu, Tykerb, Arzerra, osilodrostat and Signifor. Prior to moving to Oncology Global Drug Development in 2008, Germo served in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas, including Global Therapeutic Area Head, Project Management at Novartis in 2007 and Business Unit Head Transplantation, Nordic Region at Novartis from 2005 to 2006. Germo joined Novartis in 2001 from McKinsey & Company where he was a member of the Global Healthcare Practice. Germo was a PostDoctoral Fellow at Dartmouth Medical School and holds a Medical Doctorate from the University of Heidelberg. He studied medicine at Charité University Hospital, Berlin.

Heinz Mäusli is the Chief Financial Officer of Advanced Accelerator Applications (AAA), a Novartis company. He was a member of AAA’s board of directors from 2008 to 2014. He also serves as a member on several boards of AAA subsidiaries. Heinz joined AAA in 2003. Prior to this, he was a management consultant for Accenture from 1996 to 2001, and at Gemini Consulting from 1995 to 1996. Heinz received a Master’s degree from the University of St. Gallen in St. Gallen, Switzerland in 1988, and a Master’s degree in business administration from Columbia Business School in New York in 1995.


Barak Palatchi was appointed Chief Commercial Officer of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. Barak was Oncology General Manager, UK & Ireland for Novartis from 2016 to February 2018, and a member of the Novartis Oncology Leadership Team, Region Europe. Prior to this, Barak was Oncology General Manager Israel for Novartis from 2012 to June 2016. Before this, he was Head of Marketing for Samsung Israel from 2011 to 2012. Prior to joining Samsung, Barak spent seven years with Pfizer Israel in roles of increasing responsibility including Public Affairs Director, Marketing Director and then Business Unit Director. Barak started his career in the U.S. working as a legislative assistant for New York Congressman Eliot Engel. Barak was a scholar at the Institute for Advance Strategic and Political Studies in Washington D.C., and holds a Bachelor of Arts in Political Science from Bar-Ilan University, Israel.